J&J asked for opioid marketing data; EU approves Bayer cancer drug;

@FiercePharma: So, if you're not among the 103K people who have already, check it out. Report | Follow @FiercePharma

@EricPFierce: With a market as big as China, you can't let a bribery case scare you away. J&J, Merck to build new plants. More | Follow @EricPFierce

@CarlyHFierce: Tufts University report: 71% of revenue from the top 10 best-selling meds last year came from biotech products. More | Follow @CarlyHFierce

> Chicago authorities have subpoenaed Johnson & Johnson ($JNJ) over its marketing of the Duragesic patch and Nucynta tablet. Story

> The European Commission has approved Bayer's new prostate cancer drug Xofigo. Report

> Sources say Sanofi ($SNY) is close to buying Mumbai-based Elder Pharmaceuticals. Story

> A new report from U.K. consultant Gold Group confirms that the majority of women execs in pharma are in lower-paying jobs. Report

Medical Device News

@FierceMedDev: Trending on FierceMedicalDevices: Report: J&J plans layoffs, revamp to jumpstart diabetes arm. Story | Follow @FierceMedDev

@MarkHFierce: NeuroPace won the FDA's blessing for a neurostimulation implant to treat epilepsy. More | Follow @MarkHFierce

@MichaelGFierce: Next-gen sequencing tech from GenapSys nets $37M round. Item | Follow @MichaelGFierce

> In a blow to Edwards, German court restores Medtronic's right to sell heart valve. Article

> As other IPOs move forward, CardioDx pulls back. More

> Kimberly-Clark seeks to spin off healthcare, medical devices arm. News

Biotech News

@FierceBiotech: Baxter bets $60M on Cell Therapeutics' blood cancer drug. Article | Follow @FierceBiotech

@JohnCFierce: Vanda jumps again as FDA panel smiles on sleep-disorder drug. More | Follow @JohnCFierce

@DamianFierce: ICYMI: Sanofi gets mixed FDA blessing for MS drug Lemtrada. Story | Follow @DamianFierce

@EmilyMFierce: From FierceBiotech Research: Tekmira's RNAi antivirals protect animals from lethal doses of Ebola, Marburg. Article | Follow @EmilyMFierce

> Catabasis nails $32.4M for triglyceride-busting drug. News

> Zafgen obesity drug scores heavyweight success in PhII trial. More

> Relax, PCSK9ers: FDA won't roadblock blockbusters from Sanofi, Amgen. Story

And Finally... A study by IMS Healthcare Informatics says that more than 90% of consumer mobile healthcare apps are targeted at the wrong demographic and of limited value. Story

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.